SELB
Selecta Biosciences Earlier Reported Q2 EPS $0.06, Sales $39.27M Up From $19.66M YoY
Benzinga
Selecta Biosciences Inc NASDAQ: SELB
SELB
GoSymbol lookup
Health Care : Biotechnology | Small Cap BlendCompany profile
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company leverages its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. It enables the re-dosing of life-saving gene therapies and restoring self-tolerance in autoimmune diseases. The ImmTOR platform reduces the formation of anti-drug antibodies (ADAs), against biologic drugs and restore self-tolerance to auto-antigens in autoimmune diseases. ImmTOR leverages nanoparticle technology to target rapamycin, an immunomodulatory drug, to antigen presenting cells to generate antigen-specific immune tolerance when combined with the antigen of interest. Its nanoparticles are designed to remain intact after injection into the body and accumulate predominantly in lymph nodes, the spleen, and the liver, where the immune response is coordinated. Its product candidate, SEL-212, which is in Phase III clinical development includes pegadricase, a pegylated uricase enzyme.
